Once-Daily Tiotropium Respimat® Add-On Therapy Has a Safety Profile Comparable With Placebo in Children and Adolescents
Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2016.12.308
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 2017
Authors
Publisher
Elsevier BV